A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Oncoinvent Solutions AS
Oncoinvent Solutions AS
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
University of Kentucky
Corcept Therapeutics
University of Chicago
Columbia University
Institut Bergonié
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
OncoNano Medicine, Inc.
Albert Einstein College of Medicine
M.D. Anderson Cancer Center
Ciusss de L'Est de l'Île de Montréal
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gustave Roussy, Cancer Campus, Grand Paris
University Hospital, Ghent
University Hospital, Ghent
University of Kansas Medical Center
Instituto do Cancer do Estado de São Paulo
Odense University Hospital
Odense University Hospital
Sun Yat-sen University
University of California, San Diego
Gangnam Severance Hospital
University Hospital, Geneva
Eli Lilly and Company
Sheba Medical Center
Catharina Ziekenhuis Eindhoven
National Institutes of Health Clinical Center (CC)
UMC Utrecht
Hospices Civils de Lyon
Neovii Biotech
University of Regensburg
AIO-Studien-gGmbH
Odense University Hospital
Maimónides Biomedical Research Institute of Córdoba
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Galenic Research Institute Ltd
Hospital General Universitario Gregorio Marañon
Japan Clinical Oncology Group
University Hospital, Gasthuisberg
National Institutes of Health Clinical Center (CC)
Morphotek
Jules Bordet Institute
University of Southern California
Uppsala University
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Facet Biotech
National Institutes of Health Clinical Center (CC)